cend
cend.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Read more
Report
CEND-1 Offers Hope in Advanced Pancreatic Cancer
Phase I study showed good safety profile, no dose-limiting toxicities, and encouraging activity
Read more
Report
Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (
Read more
Report
Phase Ib/IIa trial of CEND-1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).
Read more
Report
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
--Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, and Cend Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focuse
Read more
Report
Cend Therapeutics Announces Acquisition of Impilo Therapeutics
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend's drug delivery capabilities to create a unique platform f
Read more
Report